Georgia Capital 3Q23 & 9M23 Performance Overview
CLINICS & DIAGNOSTICS BUSINESS
OPERATING PERFORMANCE OVERVIEW
REVENUE DEVELOPMENT²
CLINICS & DIAGNOSTICS
KEY DRIVERS
The y-o-y increase in total revenues in 3Q23 is
attributable to higher demand for non-COVID
regular ambulatory services and the expansion
of the business.
■ Similar to the hospitals business, the new
facility regulation, also affected community
clinics. In certain departments, admissions were
temporarily suspended due to renovation works.
☐
In 3Q23, the business sold one of its polyclinic
buildings for US$ 6.2 million. The gain from this
transaction amounted to GEL 2.9 million.
GEL MILLION
19
+7.9%
20
20
4
14
16
3Q22
3Q23
■Clinics Diagnostics - Total
KEY OPERATING HIGHLIGHTS
99
65
-1.3%
65
16
13
51
49
EBITDA¹ DEVELOPMENT
GEORGIA
CAPITAL
+33.8%
11
NMF
8
1
5
10
7
1
5
9M22
9M23
3Q22
3Q23
9M22
9M23
■Clinics
Diagnostics
Clinics
3Q22
VS.
■ 3Q23
Change y-o-y
9M22
VS.
■ 9M23
Number of admissions ('000)
Number of registered patients ('000)
Diagnostics
1,619.8
1,481.8
Change y-o-y
-8.5%
483.8
460.3
-4.9%
608.3
632.2 +3.9%
608.3
632.2
+3.9%
Number of patients served ('000)
Number of total tests performed ('000)
208
501
164
-20.9%
+11.8%
762
560
1,799
577
1,810
-24.3%
+0.6%
Georgia Capital PLC 1. Excluding IFRS 16. 2. Total revenue excludes eliminations between the clinics & diagnostics business lines.
72View entire presentation